Hepatitis C, Chronic

• 

  Subject Areas on Research

  • "If I Get Cured, My Whole Quality of Life Will Change": Patients' Anticipated and Actualized Benefits Following Cure from Chronic Hepatitis C. 
  • A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure. 
  • A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: The PRIORITIZE Study. 
  • A comprehensive assessment of patient reported symptom burden, medical comorbidities, and functional well being in patients initiating direct acting antiviral therapy for chronic hepatitis C: Results from a large US multi-center observational study. 
  • A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C virus infection. 
  • A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection. 
  • A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats. 
  • A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. 
  • A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. 
  • A phase I trial of an antisense inhibitor of hepatitis C virus (ISIS 14803), administered to chronic hepatitis C patients. 
  • A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. 
  • A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C. 
  • Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. 
  • Acute HCV: the early bird catches the virus. 
  • Adaptive Challenges and Family Support: Patient Self-Management during Treatment for Chronic Hepatitis C. 
  • Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination. 
  • Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers. 
  • Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. 
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1. 
  • Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. 
  • American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases. 
  • An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. 
  • An integrated alcohol abuse and medical treatment model for patients with hepatitis C. 
  • Antibody-selected mimics of hepatitis C virus hypervariable region 1 activate both primary and memory Th lymphocytes. 
  • Antiproliferative effects of interferon alpha on hepatic progenitor cells in vitro and in vivo. 
  • Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. 
  • Approach to the treatment-naïve patient with HCV genotype 1 infection. 
  • Association between hypothyroidism and hepatocellular carcinoma: a case-control study in the United States. 
  • Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. 
  • Benefits of Direct-Acting Antivirals for Hepatitis C. 
  • Birth cohort screening for chronic hepatitis during colonoscopy appointments. 
  • Boceprevir for HCV in patients with HIV: where next? 
  • Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response. 
  • Boceprevir for untreated chronic HCV genotype 1 infection. 
  • Cardiac dysfunction associated with a nucleotide polymerase inhibitor for treatment of hepatitis C. 
  • Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C. 
  • Chronic hepatitis C and antiviral treatment regimens: where can psychology contribute? 
  • Chronic hepatitis C: an age wave of disease burden. 
  • Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. 
  • Commentary: The Field Moves Forward. 
  • Commentary: the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument. 
  • Comments on cochrane review on direct-acting antivirals for hepatitis C. 
  • Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. 
  • Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. 
  • Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response. 
  • Curing hepatitis C virus (HCV) after organ transplantation: Increased risk of rejection following HCV elimination. 
  • Current therapies for chronic hepatitis C. Drug combination achieves sustained response in more than half of patients. 
  • Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. 
  • Diagnosis and treatment of chronic hepatitis C infection. 
  • Dialysis-requiring acute kidney injury among hospitalized adults with documented hepatitis C Virus infection: a nationwide inpatient sample analysis. 
  • Differential prevalence and geographic distribution of hepatitis C virus genotypes in acute and chronic hepatitis C patients in Vietnam. 
  • Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. 
  • Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. 
  • Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. 
  • Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. 
  • Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. 
  • Effect of bilirubin UDP glucuronosyltransferase 1 gene TATA box genotypes on serum bilirubin concentrations in chronic liver injuries. 
  • Effect of different types of smoking and synergism with hepatitis C virus on risk of hepatocellular carcinoma in American men and women: case-control study. 
  • Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. 
  • Effect of sofosbuvir and ribavirin treatment on peripheral and hepatic lipid metabolism in chronic hepatitis C virus, genotype 1-infected patients. 
  • Effects of Sofosbuvir-Based Hepatitis C Treatment Regimens on Calcineurin Inhibitor Dosing in Liver and Kidney Transplant Recipients. 
  • Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. 
  • Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection. 
  • Elevated CD4+/CD25+ T cell frequency and function during acute hepatitis C presage chronic evolution. 
  • Elevated serum CK18 levels in chronic hepatitis C patients are associated with advanced fibrosis but not steatosis. 
  • Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals. 
  • Erythropoietic response to anemia in chronic hepatitis C patients receiving combination pegylated interferon/ribavirin. 
  • Erythropoietin for ribavirin-induced anemia in hepatitis C: more answers but many more questions. 
  • Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. 
  • Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection. 
  • Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers. 
  • Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. 
  • FibroSURE and FibroScan in relation to treatment response in chronic hepatitis C virus. 
  • Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection. 
  • From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. 
  • Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. 
  • Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection. 
  • Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. 
  • Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. 
  • Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study. 
  • Growth factors during HCV therapy may be "cost-effective", but are they "effective"? 
  • HIV/HCV-coinfected natural viral suppressors have better virologic responses to PEG-IFN and ribavirin than ARV-treated HIV/HCV patients. 
  • HLA class I allelic diversity and progression of fibrosis in patients with chronic hepatitis C. 
  • Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. 
  • Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. 
  • Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. 
  • Hepatitis B virus viral load and treatment decision. 
  • Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. 
  • Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure. 
  • Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients? 
  • Hepatitis C Virus, Inflammation, and Cellular Aging: Turning Back Time. 
  • Hepatitis C and depressive symptoms: psychological and social factors matter more than liver injury. 
  • Hepatitis C and steatosis. 
  • Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. 
  • Hepatitis C in pregnancy: screening, treatment, and management. 
  • Hepatitis C pharmacogenetics: state of the art in 2010. 
  • Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. 
  • Hepatitis C virus directly acting antivirals: current developments with NS3/4A HCV serine protease inhibitors. 
  • Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner. 
  • Hepatitis C virus-related cryoglobulinemic vasculitis: emerging trends in therapy. 
  • Hepatitis-C-virus-induced microRNAs dampen interferon-mediated antiviral signaling. 
  • High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. 
  • IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. 
  • IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin. 
  • IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies. 
  • IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. 
  • IL28B polymorphism is not associated with HCV protease diversity in patients co-infected with HIV and HCV treated with pegylated interferon and ribavirin. 
  • ITPA gene polymorphisms significantly affect hemoglobin decline and treatment outcomes in patients coinfected with HIV and HCV. 
  • ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. 
  • Impact of EGF, IL28B, and PNPLA3 polymorphisms on the outcome of allograft hepatitis C: a multicenter study. 
  • Impact of IL28B gene polymorphisms on interferon-λ3 plasma levels during pegylated interferon-α/ribavirin therapy for chronic hepatitis C in patients coinfected with HIV. 
  • Impact of Substance Use Disorder on the Rate of Sustained Virological Response in Veterans With Chronic Hepatitis C Treated With Direct-Acting Antivirals. 
  • Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence. 
  • Improved Survival After Liver Transplantation for Patients With Human Immunodeficiency Virus (HIV) and HIV/Hepatitis C Virus Coinfection in the Integrase Strand Transfer Inhibitor and Direct-Acting Antiviral Eras. 
  • In the clinic. Hepatitis C. 
  • Incidence of Drug Interactions Identified by Clinical Pharmacists in Veterans Initiating Treatment for Chronic Hepatitis C Infection. 
  • Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy. 
  • Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. 
  • Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. 
  • Initial treatment for chronic hepatitis C: current therapies and their optimal dosing and duration. 
  • Innovations in Heart Transplantation: A Review. 
  • Inosine triphosphatase deficiency helps predict anaemia, anaemia management and response in chronic hepatitis C therapy. 
  • Insulin resistance and steatosis in hepatitis C virus infection. 
  • Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. 
  • Interferon (IFN)-alpha activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-alpha in vivo. 
  • Interferon and ribavirin therapy does not select for resistance mutations in hepatitis C virus polymerase. 
  • Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection. 
  • Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. 
  • Interleukin 28B polymorphisms are the only common genetic variants associated with low-density lipoprotein cholesterol (LDL-C) in genotype-1 chronic hepatitis C and determine the association between LDL-C and treatment response. 
  • Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. 
  • Kinetics of hepatitis C virus reinfection after liver transplantation. 
  • Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. 
  • Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. 
  • Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. 
  • Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. 
  • Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. 
  • Levels of alanine aminotransferase confound use of transient elastography to diagnose fibrosis in patients with chronic hepatitis C virus infection. 
  • Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection. 
  • Long-term Patient-Centered Outcomes in Cirrhotic Patients With Chronic Hepatitis C After Achieving Sustained Virologic Response. 
  • Longitudinal assessment of hepatitis C fibrosis progression by collagen and smooth muscle actin morphometry in comparison to serum markers. 
  • Lost in translation? IL28B's discovery and the journey back to the patient. 
  • Making it happen: managed care considerations in vanquishing hepatitis C. 
  • Management of hepatitis C virus infection: the basics. 
  • Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. 
  • Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals. 
  • Metabolic Dysregulation in Hepacivirus Infection of Common Marmosets (Callithrix jacchus). 
  • Metaprotein expression modeling for label-free quantitative proteomics. 
  • MicroRNA-122 associates with serum apolipoprotein B but not liver fibrosis markers in CHC genotype 1 infection. 
  • Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. 
  • Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. 
  • Natural products and chronic hepatitis C virus. 
  • New therapies for chronic hepatitis C virus infection. 
  • Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. 
  • Noninvasive prediction of fibrosis in patients with chronic hepatitis C. 
  • Not Achieving Sustained Viral Eradication of Hepatitis C Virus After Treatment Leads to Worsening Patient-reported Outcomes. 
  • Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. 
  • Open-label, ascending dose, prospective cohort study evaluating the antiviral efficacy of Rosuvastatin therapy in serum and lipid fractions in patients with chronic hepatitis C. 
  • Optimal Timing of Administration of Direct-acting Antivirals for Patients With Hepatitis C-associated Hepatocellular Carcinoma Undergoing Liver Transplantation. 
  • Osteopontin is up-regulated in chronic hepatitis C and is associated with cellular permissiveness for hepatitis C virus replication. 
  • Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. 
  • PHOTON-2: hope for patients with HIV and HCV co-infection? 
  • Patient engagement and study design of PROP UP: A multi-site patient-centered prospective observational study of patients undergoing hepatitis C treatment. 
  • Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C). 
  • Patient-reported outcomes 12 months after hepatitis C treatment with direct-acting antivirals: Results from the PROP UP study. 
  • Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. 
  • Patients With Nonalcoholic Steatohepatitis Experience Severe Impairment of Health-Related Quality of Life. 
  • Patients with chronic hepatitis C undergoing watchful waiting: Exploring trajectories of illness uncertainty and fatigue. 
  • Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. 
  • Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients. 
  • Performance of the AST-to-platelet ratio index as a noninvasive marker of fibrosis in pediatric patients with chronic viral hepatitis. 
  • PharmGKB summary: peginterferon-α pathway. 
  • Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. 
  • Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. 
  • Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. 
  • Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. 
  • Population-based hepatitis C surveillance and treatment in a national managed care organization. 
  • Portosystemic shunts in children: a 15-year experience. 
  • Positive serum cryoglobulin is associated with worse outcome after liver transplantation for chronic hepatitis C. 
  • Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index. 
  • Prediction of treatment week eight response & sustained virologic response in patients treated with boceprevir plus peginterferon alfa and ribavirin. 
  • Predictors of consent to pharmacogenomics testing in the IDEAL study. 
  • Primary central nervous system lymphoma, presenting as diabetes insipidus, as a sequela of hepatitis C. 
  • Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. 
  • Psychometric properties of the PROMIS short form measures in a U.S. cohort of 961 patients with chronic hepatitis C prescribed direct acting antiviral therapy. 
  • Quantitation of pretreatment serum interferon-γ-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. 
  • Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. 
  • Reduced Alcohol Use Is Sustained in Patients Provided Alcohol-Related Counseling During Direct-Acting Antiviral Therapy for Hepatitis C. 
  • Relationship of smoking and fibrosis in patients with chronic hepatitis C. 
  • Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin. 
  • Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. 
  • Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)". 
  • Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response. 
  • Retrodisplaced gallbladder detected on hepatobiliary scintigraphy. 
  • Retrospective clinicopathologic correlation of gross tumor size of hepatocellular carcinoma: implications for stereotactic body radiotherapy. 
  • Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper? 
  • Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. 
  • Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C. 
  • Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. 
  • Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. 
  • Safety and efficacy of ledipasvir-sofosbuvir in black patients with hepatitis C virus infection: A retrospective analysis of phase 3 data. 
  • Safety profile of boceprevir and telaprevir in chronic hepatitis C: real world experience from HCV-TARGET. 
  • Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy. 
  • Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys. 
  • Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. 
  • Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in pregnancy-updated guidelines: Replaces Consult Number 43, November 2017. 
  • Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. 
  • Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. 
  • Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. 
  • Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. 
  • Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. 
  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. 
  • Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. 
  • Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment. 
  • Steatosis and chronic hepatitis C virus infection: mechanisms and significance. 
  • Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. 
  • Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir. 
  • Supportive Interventions During Treatment of Chronic Hepatitis C: A Review of the Literature. 
  • Sustainable and equivalent improvements in symptoms and functional well-being following viral cure from ledipasvir/sofosbuvir versus elbasvir/grazoprevir for chronic hepatitis C infection: Findings from the randomized PRIORITIZE trial. 
  • Sustained viral response after interferon-based therapy in chronic hepatitis C: more evidence to support a life-long cure. 
  • Sustained virologic response rates with telaprevir-based therapy in treatment-naive patients evaluated by race or ethnicity. 
  • Symptoms and functioning improve after chronic hepatitis C cure as assessed by the Memorial Symptom Assessment Scale and PROMIS measures. 
  • Systems biological analyses reveal the hepatitis C virus (HCV)-specific regulation of hematopoietic development. 
  • T lymphocytes from chronic HCV-infected patients are primed for activation-induced apoptosis and express unique pro-apoptotic gene signature. 
  • Telaprevir for previously treated chronic HCV infection. 
  • Telaprevir for previously untreated chronic hepatitis C virus infection. 
  • Telaprevir for the treatment of chronic hepatitis C infection. 
  • Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. 
  • The Hepatitis C-Alcohol Reduction Treatment (Hep ART) intervention: Study protocol of a multi-center randomized controlled trial. 
  • The acidic domain of the hepatitis C virus NS4A protein is required for viral assembly and envelopment through interactions with the viral E1 glycoprotein. 
  • The association of genetic variants with hepatic steatosis in patients with genotype 1 chronic hepatitis C infection. 
  • The changing epidemiology of HIV-related chronic kidney disease in the era of antiretroviral therapy. 
  • The clinical management of HCV in the HIV-infected patient. 
  • The clinical utility of using Catrimox-14-treated whole blood in detecting hepatitis C virus RNA. 
  • The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. 
  • The natural history of hepatitis C viral infection. 
  • The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. 
  • The protease inhibitor era: an opportunity to improve the quality of care. 
  • The rapid evolution of treatment strategies for hepatitis C. 
  • The rate of fibrosis progression is an independent predictor of the response to antiviral therapy in chronic hepatitis C. 
  • The use of complementary and alternative medicine by patients with chronic hepatitis C. 
  • The use of mind-body medicine and prayer among adult patients with chronic hepatitis C. 
  • Tinkering and tailoring with HCV therapy: can we get away with less? 
  • Transient CD86 expression on hepatitis C virus-specific CD8+ T cells in acute infection is linked to sufficient IL-2 signaling. 
  • Transplant versus resection for the management of hepatocellular carcinoma meeting Milan Criteria in the MELD exception era at a single institution in a UNOS region with short wait times. 
  • Transplantation-mediated alloimmune thrombocytopenia: Guidelines for utilization of thrombocytopenic donors. 
  • Treating HCV Infection: It Doesn't Get Much Better Than This. 
  • Treatment of HCV infection by targeting microRNA. 
  • Treatment of acute hepatitis C with interferon alfa-2b. 
  • Treatment of chronic hepatitis C in blacks and non-Hispanic whites. 
  • Treatment of genotype 1 HCV infection in the HIV coinfected patient in 2014. 
  • Treatment of hepatitis C in special populations. 
  • Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir. 
  • Trends in hepatitis C treatment uptake in the United States. 
  • Uncertainty, symptoms, and quality of life in persons with chronic hepatitis C. 
  • Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication. 
  • Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. 
  • Validation of a simple predictive model for the identification of mild hepatic fibrosis in chronic hepatitis C patients. 
  • Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. 
  • Vibration-Controlled Transient Elastography for Diagnosing Cirrhosis and Staging Hepatic Fibrosis. 
  • Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3. 
  • Viral factors induce Hedgehog pathway activation in humans with viral hepatitis, cirrhosis, and hepatocellular carcinoma. 
  • Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. 
  • Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. 
  • Watchful waiting: role of disease progression on uncertainty and depressive symptoms in patients with chronic hepatitis C. 
  • Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression and drinking motives. 
• 

  Keywords of People

  • Choi, Steven Sok, Associate Professor of Medicine, Medicine, Gastroenterology